Rituximab for childhood-onset nephrotic syndrome

The Lancet

Volumn 384, Issue 9950, 2014, Pages 1242-1243

  Hodson, Elisabeth M ^a,b   Craig, Jonathan C ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; NEPHROTIC SYNDROME; NOTE; ONSET AGE; PRIORITY JOURNAL; TIME TO TREATMENT; FEMALE; MALE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEPHROTIC SYNDROME;

EID: 84923530550     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60654-1     Document Type: Note

References (14)

1. Lombel RM, Gipson DS, Hodson EM. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013; 28: 415-26.
2. Hamasaki Y, Yoshikawa N, Hattori S, et al. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2009; 24: 2177-85.
3. Pravitsitthikul N, Willis NS, Hodson EM, Craig JC. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 2013; 10: CD002290.
4. Kemper MJ, Gellermann J, Habbig S, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012; 27: 1910-15.
5. Ravani P, Ponticelli A, Siciliano C, et al. Rituximab is a safe and eff ective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 2013; 84: 1025-33.
6. Tellier S, Brochard K, Garnier A, et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol 2013; 28: 911-18.
7. Sellier-Leclerc A-L, Belli E, Guerin V, Dorfmuller P, Deschenes G. Fulminant viral myocarditis after rituximab in pediatric nephrotic syndrome. Pediatr Nephrol 2013; 28: 1875-79.
8. Chaumais M-C, Garnier A, Chalard F, et al. Fatal pulmonary fi brosis after rituximab administration. Pediatr Nephrol 2009; 24: 1753-55.
9. Czarniak P, Zaluska-Lesniewska I, Zagozdzon I, Zurowska A. Diffi culties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2013; 29: 987-88.
10. Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 2010; 126: e243-46.
11. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-40.
12. Ravani P, Magnasco A, Edefonti A, et al. Short-term eff ects of rituximab in children with steroid-and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 1308-15.
13. Iijima K, Sako M, Nozu K, et al, on behalf of the Rituximab for Childhoodonset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014; published online June 23. http://dx.doi.org/10.1016/S0140-6736(14)60541-9.
14. Boyer O, Niaudet P. Rituximab in childhood steroid-dependent nephrotic syndrome. Nat Rev Nephrol 2013; 9: 562-63.